Paratek Makes Two Senior Appointments
This article was originally published in Scrip
Paratek Pharmaceuticals, Inc. has appointed Regina Paglia senior vice-president of human resources and Dr. Stephen Villano vice-president of clinical and medical affairs. Paglia has been vice-president and senior vice-president of human resources at companies such as Mascoma Corp., and Sepracor Pharmaceuticals, Inc., now Sunovion Pharmaceuticals Corp. Most recently she was vice-president of human resources at Myriant Corp., a bio-chemical company. Villano brings over 20 years' experience in antiviral and anti-infective research to Paratek and was previously vice-president of clinical research and development at ViroPharma, Inc. Before this, he was medical director of virology, medical science and development at Dupont Pharmaceuticals.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.